Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series

The COVID‐19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT‐P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT‐P13 SC suggest that patients receiving IV inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraliakos, Xenofon, Tsiami, Styliani, Vijayan, Sooraj, Jung, Haewon, Barkham, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777045/
https://www.ncbi.nlm.nih.gov/pubmed/35079380
http://dx.doi.org/10.1002/ccr3.5205
Descripción
Sumario:The COVID‐19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT‐P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT‐P13 SC suggest that patients receiving IV infliximab should be offered a switch to CT‐P13 SC.

Ejemplares similares